You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 31 No. 1, July 1974 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Antischizophrenic Drugs and Brain Cholinergic Receptors

Affinity for Muscarinic Sites Predicts Extrapyramidal Effects

Solomon Snyder, MD; David Greenberg; Henry I. Yamamura, PhD

Arch Gen Psychiatry. 1974;31(1):58-61.


Abstract

With only a few exceptions, the phenothiazines and butyrophenones used in the treatment of schizophrenia appear to exert antischizophrenic actions to the same or closely similar degrees.

Both antischizophrenic and extrapyramidal effects apparently result from dopamine receptor blockade. Here, we report the influence of a variety of such antischizophrenic drugs on the brain's receptor for the muscarinic action of acetylcholine.

Extrapyramidal effects are inversely proportional to affinity for the muscarinic receptor. Thus, drugs such as clozapine and thioridazine hydrochloride apparently owe their low incidence of extrapyramidal effects to anticholinergic properties that compensate for their intrinsic extrapyramidal effects. Our findings provide a means to predict extrapyramidal actions of new potential antischizophrenic drugs.



Author Affiliations

Baltimore

From the departments of psychiatry and pharmacology, the Johns Hopkins University School of Medicine, Baltimore.


Footnotes

Accepted for publication Feb 28, 1974.

Reprint requests to the Johns Hopkins University School of Medicine, Department of Pharmacology and Experimental Therapeutics, 725 N Wolfe St, Baltimore, MD 21205 (Dr. Snyder).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Effects of Clozapine and Risperidone on Spatial Working Memory in Schizophrenia
McGurk et al.
Am. J. Psychiatry 2005;162:1013-1016.
ABSTRACT | FULL TEXT  

Association of Anticholinergic Load With Impairment of Complex Attention and Memory in Schizophrenia
Minzenberg et al.
Am. J. Psychiatry 2004;161:116-124.
ABSTRACT | FULL TEXT  

Delayed Onset of Oculogyric Crisis and Torticollis with Intramuscular Haloperidol
Jhee et al.
The Annals of Pharmacotherapy 2003;37:1434-1437.
ABSTRACT | FULL TEXT  

Forty Years of Neurotransmitters: A Personal Account
Snyder
Arch Gen Psychiatry 2002;59:983-994.
ABSTRACT | FULL TEXT  

Medication-Induced Dystonias in Nine Patients With Dementia
Magnuson et al.
J. Neuropsychiatry Clin. Neurosi. 2000;12:219-225.
ABSTRACT | FULL TEXT  

Clinical Assessment of Extrapyramidal Signs in Nursing Home Patients Given Antipsychotic Medication
Avorn et al.
Arch Intern Med 1994;154:1113-1117.
ABSTRACT  

Extending neurotransmitter hypotheses of neuroleptic action and schizophrenia beyond cell-surface receptors. The phosphoinositide signalling system provides a link between receptors and intracellular calcium
Essali and Hirsch
J Psychopharmacol 1992;6:453-461.
 

Snipping the Thread of Life: Antimuscarinic Side Effects of Medications in the Elderly
Peters
Arch Intern Med 1989;149:2414-2420.
ABSTRACT  

Cholinergic Hyperactivity and Negative Schizophrenic Symptoms: A Model of Cholinergic/Dopaminergic Interactions in Schizophrenia
Tandon and Greden
Arch Gen Psychiatry 1989;46:745-753.
ABSTRACT  

Parkinsonism Following Neuroleptic Withdrawal
Ceccherini Nelli et al.
Arch Gen Psychiatry 1989;46:383-384.
ABSTRACT  

Initial Anticholinergic Prophylaxis for Neuroleptic-Induced Extrapyramidal Syndromes
Keepers et al.
Arch Gen Psychiatry 1983;40:1113-1117.
ABSTRACT  

Drug-Induced and Other Orofacial-Cervical Dyskinesias
JANKOVIC
ANN INTERN MED 1981;94:788-793.
ABSTRACT  

Serum Levels of Anticholinergic Drugs in Treatment of Acute Extrapyramidal Side Effects
Tune and Coyle
Arch Gen Psychiatry 1980;37:293-297.
ABSTRACT  

Clozapine, Chlorpromazine, and Placebo in Newly Hospitalized, Acutely Schizophrenic Patients: A Controlled, Double-Blind Comparison
Shopsin et al.
Arch Gen Psychiatry 1979;36:657-664.
ABSTRACT  

Antidepressants and the Muscarinic Acetylcholine Receptor
Snyder and Yamamura
Arch Gen Psychiatry 1977;34:236-239.
ABSTRACT  

Thioridazine Stimulates Prolactin Secretion in Man
Sachar et al.
Arch Gen Psychiatry 1975;32:885-886.
ABSTRACT  

Dopamine receptors in the brain
Iversen
Science 1975;188:1084-1089.
 

Physostigmine: Its Use in Acute Anticholinergic Syndrome With Antidepressant and Antiparkinson Drugs
Granacher and Baldessarini
Arch Gen Psychiatry 1975;32:375-380.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1974 American Medical Association. All Rights Reserved.